Aptamer Group updates on progress in Unilever partnership

Unilever plc

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has provided an update on the partnership with Unilever to deliver Optimer binders for cosmetic applications.

In 2022, Aptamer initiated a partnership with Unilever for the development of Optimer binders with the aim of treating malodour in personal care products. Following successful Optimer development, the binders have been rigorously tested at both Aptamer Group and Unilever showing highly positive and reproducible results, indicating their potential for use in downstream products.

Based on these results, a patent was submitted on 28 March 2024, to protect the developed Optimer binders and give Aptamer Group precedence for the protection of the intellectual property.

Work to test the Optimer binders is ongoing in Unilever’s labs. Unilever plans to conduct on-person functionality studies in the second half of 2024.

The global deodorant market alone was valued at $25.6 billion in 2023, with Unilever being the market leader as the largest antiperspirant and deodorant manufacturer in the world.

It is anticipated that this project will be completed over the next two years, and if successful, could result in Aptamer licensing the Optimer binders to Unilever.

Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: “I’m pleased to provide this update on our work with Unilever. The early success we have seen to date in evaluating our Optimers that aim to treat malodour has been promising. We are excited to support our partners at Unilever in advancing these binders to the next stage of development with on-person functionality studies. Fast-moving consumer goods (FMCG) like personal care products can progress to market more rapidly than diagnostics or therapeutic products. Optimers offer advantages such as stability, shelf life and consistent manufacturability making them ideal molecules for FMCG / cosmetic applications.  If the Optimer binders continue to progress through the testing and manufacturing stages in Unilever’s hands, then we anticipate the completion of this project within two years.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system.

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows.

Aptamer Group secures £270k in new orders and first cash licensing receipts

Aptamer Group plc has announced £190,000 in new fee-for-service Optimer® orders and £80,000 in cash licensing receipts, including its first payment from a hot-start PCR licence.

Aptamer reports 27% revenue growth and signs multiple licensing deals in H1 FY26

Aptamer Group reported unaudited revenue of £0.83 million for the six months to 31 December 2025, a 27% increase year on year, supported by strong fee-for-service demand and the signing of multiple licensing agreements.

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products.

Aptamer Group AGM statement highlights contract wins and growing order book

Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million.

    Search

    Search